Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy."

Transcription

1 Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine

2 Molecular testing has become the primary tool for precision medicine. NeoGenomics is a full-service cancer diagnostic laboratory committed to helping the cancer community incorporate informative, effective, and innovative tests into the care of their patients. With over 155 molecular assays in-house, we provide one of the largest oncology-focused molecular test menus available along with top-quality consultation and laboratory services in cytogenetics, FISH, flow cytometry, and IHC. NeoGenomics has developed a unique expertise in analysis and reporting of cancer biomarkers. By having one of the fastest development cycles in the industry, we are also responsive to opportunities to improve service and patient care. We rapidly bring our clients state-of-the-art tests for newly reported, significant genetic indicators for disease diagnosis and classification, assessing prognosis, and selecting therapy. Our oncology and pathology clients always have the flexibility to customize their orders to their patient s specific needs. Highlights of Our Molecular Program Include: One of the most comprehensive oncology-focused menus of single-gene and multi-parameter tumor profiles available Full range of molecular diagnostic technologies including next-gen sequencing, quantitative PCR, gold-standard Sanger sequencing, fragment analysis, and SNP microarray Extensive cell-free DNA/RNA liquid biopsy testing capabilities useful for diagnostic screening, monitoring and detecting minimal residual disease All complementary testing methods including morphology, cytogenetics, FISH, flow cytometry, and IHC are available in-house, which maximizes yield from small specimens and minimizes TAT Growing hereditary cancer testing menu using leading-edge platforms Pharma Services supporting academic institutions, pharmaceutical companies, and the biotechnology industry Testing enhancements to improve detection of low-level abnormalities in select assays through plasma analysis and high-sensitivity sequencing Molecular Testing Capabilities Somatic Germline Early Detection/ Prediction 2 NeoGenomics Laboratories

3 Solid Tumor Tests All Tumors Microsatellite Instability Analysis (MSI) NeoARRAY SNP/Cytogenetic Profile NeoLAB Solid Tumor Monitor NeoTYPE Discovery Profile for Solid Tumors NeoTYPE Precision Profile for Solid Tumors Tumor Mutation Burden Universal Expression/Fusion Profile Brain ATRX viii Analysis IDH1/IDH2 MGMT Promoter Methylation NeoTYPE Brain Tumor Profile TERT Promoter Breast NeoTYPE Breast Tumor Profile Cervical RAF NeoTYPE Cervical Tumor Profile NOTCH1 Colorectal Exon 4 Microsatellite Instability Analysis (MSI) MLH1 Promoter Methylation NeoTYPE Colorectal Tumor Profile NeoTYPE GI Predictive Profile NOTCH1 Exon 4 RAS/RAF Panel Esophageal NeoTYPE Esophageal Tumor Profile NeoTYPE GI Predictive Profile Gastric NeoTYPE Gastric Tumor Profile NeoTYPE GI Predictive Profile GIST NeoTYPE GIST Profile Lung ALK MET MET Exon 14 Deletion Analysis NeoLAB T790M - NeoTYPE Lung Tumor Profile NGS ALK, NTRK, RET, ROS1 Fusion Profile NGS ALK, RET, ROS1 Fusion Profile Oncomine Dx Target Test Melanoma NeoARRAY SNP/Cytogenetic Profile NeoTYPE Melanoma Profile TERT Promoter Ovarian NeoTYPE Ovarian Tumor Profile TP53 Soft Tissue NeoTYPE Liposarcoma Fusion Profile NeoTYPE Soft Tissue Tumor Profile NGS Comprehensive Sarcoma Fusion Profile NGS Ewing Sarcoma Fusion Profile NGS Non-Ewing Sarcoma Fusion Profile NGS Pediatric Sarcoma Fusion Profile NGS Rhabdomyosarcoma Fusion Profile Prostate Androgen Receptor Mutation Analysis HSD3B1 Genotyping NeoLAB Prostate - Thyroid HRAS NeoTYPE Thyroid Profile NGS ALK, NTRK, RET, ROS1 Fusion Profile NGS ALK, RET, ROS1 Fusion Profile NGS Thyroid Fusion Profile TERT Promoter Other Tumors HPV DNA Tissue Testing NeoTYPE Head & Neck Tumor Profile NeoTYPE Liver/Biliary Tumor Profile NeoTYPE Other Solid Tumor Profile NeoTYPE Pancreas Tumor Profile NeoGenomics Laboratories 3

4 Hematologic Diseases Leukemias AML ASXL1 CEBPA DNMT3A ETV6-RUNX1 t(12;21) FLT3 IDH1 IDH2 Inv(16) CBFB-MYH11 NeoLAB AML Profile - NeoLAB FLT3 Mutation Analysis - NeoLAB IDH2 Mutation Analysis - NeoLAB Inv(16), CBFB-MYH11 Translocation - NeoLAB (c-) Mutation Analysis - Liquid Biopsy NeoLAB Mutation Analysis - NeoLAB NPM1 Mutation Analysis - NeoLAB Mutation Analysis - NeoLAB PML-RARA Translocation, t(16;17) - Liquid Biopsy NeoTYPE AML Favorable Risk Profile NeoTYPE AML Prognostic Profile NPM1 NPM1 MRD Analysis PML-RARA t(15;17) RUNX1 RUNX1-RUNX1T1 t(8;21) TP53 APL PML-RARA t(15;17) ALL ABL1 Kinase Domain Mutation B-Cell Gene Rearrangement BCR-ABL1 t(9;22) ETV6-RUNX1 t(12;21) IgH Clonality/MRD by NGS T-Cell Beta Gene Rearrangement T-Cell Gamma Gene Rearrangement TPMT Genotyping CLL BTK Inhibitor Acquired Resistance Panel BTK IgVH NeoLAB BTK Inhibitor Acquired Resistance Panel - NeoTYPE CLL Prognostic Profile NOTCH1 PLC-Gamma-2 SF3B1 JMML NeoLAB Mutation Analysis - NeoTYPE JMML Profile PTPN11 Other Leukemias Hairy Cell: LGLL: STAT3, T-Cell Lymphomas B-Cell Gene Rearrangement BCL1 t(11;14) BCL2 t(14;18) BTK Inhibitor Acquired Resistance Panel BTK Inhibitor Primary Susceptibility Panel EZH2 IgH Clonality/MRD by NGS MYD88 NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile NeoTYPE Lymphoma Profile RHOA Mutation Analysis T-Cell Beta Gene Rearrangement T-Cell Gamma Gene Rearrangement TET2 Myelodysplastic Syndromes ASXL1 ETV6 EZH2 NeoARRAY SNP/Cytogenetic Profile NeoLAB Mutation Analysis - NeoLAB Mutation Analysis - NeoLAB MDS/CMML Profile - NeoTYPE MDS/CMML Profile PPM1D RUNX1 SF3B1 TET2 TP53 Myeloproliferative Neoplasms BCR-ABL1 t(9;22) BCR-ABL p230 CALR JAK2 Exon JAK2 V617F MPL MPN Extended Reflex Panel MPN Standard Reflex Panel NeoLAB Mutation Analysis - NeoTYPE MPN Profile CML ABL1 BCR-ABL1 t(9;22) CSF3R for acml Plasma Cell Myeloma B-Cell Gene Rearrangement Transplant Chimerism/DNA Fingerprinting 4 NeoGenomics Laboratories

5 Hereditary Cancer Tests BRCA1 Mutation & Del/Dup Analysis BRCA1/2 Mutation & Del/Dup Analysis BRCA2 Mutation & Del/Dup Analysis T790M Germline Mutation Analysis Hereditary Cancer Comprehensive Panel Hereditary Cancer Susceptibility for Pediatrics Hereditary DNA Repair Panel for Prostate Cancer HOXB13 Genotyping Inherited Bone Marrow Failure Panel Lynch Syndrome NeoLAB Tests NeoLAB AML Profile - NeoLAB BTK Inhibitor Acquired Resistance Panel - NeoLAB T790M - NeoLAB FLT3 Mutation Analysis - NeoLAB IDH1 Mutation Analysis - NeoLAB IDH2 Mutation Analysis - NeoLAB inv(16), CBFB-MYH11 Translocation - NeoLAB (c-) Mutation Analysis - NeoLAB Mutation Analysis - NeoLAB MDS/CMML Profile - NeoLAB Myeloid Disorders Profile - NeoLAB NPM1 Mutation Analysis - NeoLAB Mutation Analysis - NeoLAB PML-RARA Translocation, t(15;17) - NeoLAB Prostate - NeoLAB RUNX1-RUNX1T1 (AML-ETO) - NeoLAB Solid Tumor Monitor - NeoGenomics Laboratories 5

6 Test Menu Single Gene Tests ABL1 Kinase Domain ALK Androgen Receptor ASXL1 ATRX B-Cell Gene Rearrangement BCL1 Translocation, t(11;14) BCL2 Translocation, t(14;18) BCR-ABL1 Non-Standard p230 BCR-ABL1 Standard p210, p190 BRCA1 Mutation & Del/Dup Analysis BRCA2 Mutation & Del/Dup Analysis BTK CALR CARD11 CBL CD79B CEBPA Chimerism/DNA Fingerprinting CSF3R CXCR4 DNMT3A T790M Germline Mutation Analysis viii Analysis EPCAM Mutation & Del/Dup Analysis ETV6 ETV6-RUNX1 Translocation, t(12;21) EZH2 FLT3 GNAS HOXB13 Genotyping HPV DNA Tissue Testing HRAS HSD3B1 Genotyping IDH1 & IDH2 IgH Clonality/MRD by NGS IgVH Inv(16), CBFB-MYH11 Translocation JAK2 Exon JAK2 V617F Exon 4 MET (c-met) MET Exon 14 Deletion Analysis MGMT Promoter Methylation Microsatellite Instability MLH1 Mutation & Del/Dup Analysis MLH1 Promoter Methylation MPL MYD88 MSH2 Mutation & Del/Dup Analysis MSH6 Mutation & Del/Dup Analysis NeoLAB T790M - NeoLAB FLT3 Mutation Analysis - NeoLAB IDH1 Mutation Analysis - NeoLAB IDH2 Mutation Analysis - NeoLAB inv(16), CBFB-MYH11 Translocation - NeoLAB (c-) Mutation Analysis - Liquid Biopsy NeoLAB Mutation Analysis - NeoLAB NPM1 Mutation Analysis - NeoLAB Mutation Analysis - NeoLAB PML-RARA Translocation, t(15;17) - NeoLAB RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21) - NOTCH1 NPM1 Exon 4 PML-RARA Translocation, t(15;17) PMS2 Mutation & Del/Dup Analysis PTPN11 PLC-Gamma-2 PMS2 Mutation & Del/Dup Analysis RHOA RUNX1 RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21) SETBP1 SF3B1 SRSF2 STAT3 T-Cell Gamma Gene Rearrangement T-Cell Beta Gene Rearrangement TERT Promoter TET2 TP53 TPMT Genotyping U2AF1 UGT1A1 Genotyping VHL WT1 ZRSR2 6 NeoGenomics Laboratories

7 Panels and Profiles AML Reflex Panel BRCA1/2 Mutation & Del/Dup Analysis BTK Inhibitor Acquired Resistance Panel BTK Inhibitor Primary Susceptibility Panel Hereditary Cancer Comprehensive Panel Hereditary Cancer Susceptibility for Pediatrics Hereditary DNA Repair Panel for Prostate Cancer Inherited Bone Marrow Failure Panel Lynch Syndrome MPN Extended Reflex Panel MPN Standard Reflex Panel NeoARRAY SNP/Cytogenetic Profile NeoLAB AML Profile - NeoLAB BTK Inhibitor Acquired Resistance Panel - NeoLAB MDS/CMML Profile - NeoLAB Myeloid Disorders Profile - NeoLAB Prostate - Liquid to Biopsy NeoLAB Solid Tumor Monitor - NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile NeoTYPE AML Favorable-Risk Profile NeoTYPE AML Prognostic Profile NeoTYPE Brain Tumor Profile NeoTYPE Breast Tumor Profile NeoTYPE Cervical Tumor Profile NeoTYPE CLL Prognostic Profile NeoTYPE Colorectal Tumor Profile NeoTYPE Discovery Profile for Solid Tumors NeoTYPE Endometrial Tumor Profile NeoTYPE Esophageal Tumor Profile NeoTYPE Gastric Tumor Profile NeoTYPE GI Predictive Profile NeoTYPE GIST Profile NeoTYPE Head & Neck Tumor Profile NeoTYPE JMML Profile NeoTYPE Liposarcoma Fusion Profile NeoTYPE Liver/Biliary Tumor Profile NeoTYPE Lung Tumor Profile NeoTYPE Lymphoma Profile NeoTYPE MDS/CMML Profile NeoTYPE Melanoma Profile NeoTYPE MPN Profile NeoTYPE Myeloid Disorders Profile NeoTYPE Other Solid Tumor Profile NeoTYPE Ovarian Tumor Profile NeoTYPE Pancreas Tumor Profile NeoTYPE Precision Profile for Solid Tumors NeoTYPE Soft Tissue Tumor Profile NeoTYPE Thyroid Profile NGS ALK, NTRK, RET, ROS1 Fusion Profile NGS ALK, RET, ROS1 Fusion Profile NGS Comprehensive Sarcoma Fusion Profile NGS Ewing Sarcoma Fusion Profile NGS Non-Ewing Sarcoma Fusion Profile NGS Pediatric Sarcoma Fusion Profile NGS Rhabdomyosarcoma Fusion Profile NGS Thyroid Fusion Profile RAS/RAF Panel Tumor Mutation Burden Universal Fusion/Expression Profile Specimen and Ordering Information Specimen Requirements NeoGenomics molecular testing is routinely performed on blood, bone marrow aspirate, fixed cytogenetic pellets, fresh tissue, and formalin-fixed paraffin-embedded tissue of all types. Acceptable specimen types vary by test, so please see our website for requirements for the test of interest. Please inquire if you have an alternative specimen type as we can often accommodate these. Ordering Tests in panels or profiles may be ordered separately or in custom combinations. The most commonlyordered tests are shown, but for many diseases, more testing that encompasses emerging research and clinical trial opportunities is available. For an extended list of tests correlated with each tumor, please search by disease state on the NeoGenomics website. NeoGenomics Laboratories 7

8 NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories. Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information Commonwealth Dr., Suite 9 Fort Myers, FL Phone: / Fax: neogenomics.com 2018 NeoGenomics Laboratories, Inc. All Rights Reserved. All other trademarks are the property of their respective owners. Rev

The Center for PERSONALIZED DIAGNOSTICS

The Center for PERSONALIZED DIAGNOSTICS The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)

More information

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH ) Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and

More information

Prior Authorization Required: Additional Information:

Prior Authorization Required: Additional Information: Genetic Testing for Somatic Tumor Markers MP9486 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below No A first-degree relative is defined as an individual

More information

ADRL Advanced Diagnostics Research Laboratory

ADRL Advanced Diagnostics Research Laboratory ADRL Advanced Diagnostics Research Laboratory John DeCoteau, MD FRCP Department of Pathology, Division of Hematopathology University of Saskatchewan Saskatchewan Cancer Agency ADRL Project Objectives New

More information

Initial Diagnostic Workup of Acute Leukemia

Initial Diagnostic Workup of Acute Leukemia Initial Diagnostic Workup of Acute Leukemia Guideline from the College of American Pathologists (CAP) and the American Society of Hematology (ASH) Publication: Archives of Pathology and Laboratory Medicine

More information

Introduction of an NGS gene panel into the Haemato-Oncology MPN service

Introduction of an NGS gene panel into the Haemato-Oncology MPN service Introduction of an NGS gene panel into the Haemato-Oncology MPN service Dr. Anna Skowronska, Dr Jane Bryon, Dr Samuel Clokie, Dr Yvonne Wallis and Professor Mike Griffiths West Midlands Regional Genetics

More information

Click to edit Master /tle style

Click to edit Master /tle style Click to edit Master /tle style Tel: (314) 747-7337 Toll Free: (866) 450-7697 Fax: (314) 747-7336 Email: gps@wustl.edu Website: gps.wustl.edu GENETIC TESTING IN CANCER Ka/nka Vigh-Conrad, PhD Genomics

More information

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran

More information

Current Techniques in Molecular Biology Friedel Nollet, Ph.D.

Current Techniques in Molecular Biology Friedel Nollet, Ph.D. Current Techniques in Molecular Biology Friedel Nollet, Ph.D. Molecular Biology and Cytometry course May 16-17, 2013 Mol, SCK-CEN, Belgium Sanger DNA sequencing Kary Mullis received a Nobel Prize in chemistry

More information

Molecular Diagnostics of Myeloid and Lymphoid Neoplasms

Molecular Diagnostics of Myeloid and Lymphoid Neoplasms Molecular Diagnostics of Myeloid and Lymphoid Neoplasms Molecular Pathology: Principles in Clinical Practice - 2012 John Greg Howe Ph.D. Department of Laboratory Medicine Yale University School of Medicine

More information

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for

More information

Case 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX

Case 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Case 1 Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME

More information

Session 4: Summary and Conclusions

Session 4: Summary and Conclusions Session 4: Summary and Conclusions Total cases in Session 4 Myeloproliferative neoplasms 16 cases Oral #300 (CEL, NOS) Mastocytosis 2 cases Oral #156 (SM-AHN) Myeloid/lymphoid neoplasms with eosinophilia

More information

Transform genomic data into real-life results

Transform genomic data into real-life results CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for

More information

Targeted NGS in oncology and hemato-oncology using in-house designed gene panels. Joni Van der Meulen Molecular Diagnostics UZ Ghent (MDG) 24/03/2017

Targeted NGS in oncology and hemato-oncology using in-house designed gene panels. Joni Van der Meulen Molecular Diagnostics UZ Ghent (MDG) 24/03/2017 Targeted NGS in oncology and hemato-oncology using in-house designed gene panels Joni Van der Meulen Molecular Diagnostics UZ Ghent (MDG) 24/03/2017 MDG = Molecular Diagnostics UZ Ghent Center for Medical

More information

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Size of Components of Human Genome Size of haploid genome 3.3 X 10 9 DNA basepairs Estimated genetic constitution 30,000

More information

The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML: A randomized trial in patient-derived xenografts

The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML: A randomized trial in patient-derived xenografts The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML: A randomized trial in patient-derived xenografts Claudia Bruedigam, Ph.D Gordon and Jessie Gilmour Leukaemia Research Laboratory

More information

Myelodysplastic syndromes Impact of Biology. Lionel Adès Hopital Saint Louis Groupe Francophone des SMD. Épidémiologie

Myelodysplastic syndromes Impact of Biology. Lionel Adès Hopital Saint Louis Groupe Francophone des SMD. Épidémiologie Myelodysplastic syndromes Impact of Biology Lionel Adès Hopital Saint Louis Groupe Francophone des SMD Épidémiologie Incidence : 3 à 6 / 100 000 hab. / An Prédomine chez les sujets âgés Augmentation de

More information

The French national network of 28 hospital molecular genetics platforms: summary of the activity in 2009

The French national network of 28 hospital molecular genetics platforms: summary of the activity in 2009 Measure 21 care and life of patients The French national network of 28 hospital molecular genetics platforms: summary of the activity in 2009 COLLECTION reports & summaries ACCESS TO INNOVATIVE MOLECULAR

More information

Division of Genomic Diagnostics CANCER GENOMIC TEST REQUISITION Page 1 of 6

Division of Genomic Diagnostics CANCER GENOMIC TEST REQUISITION Page 1 of 6 Page 1 of 6 SHIP TO: Children s Hospital of Philadelphia, Genomic Diagnostic Laboratory, 3615 Civic Center Blvd., Abramson Research Center, 714, Philadelphia, PA 19104-4302 - Phone: (215) 590-4452 Patient

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017 LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer

More information

Targeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders

Targeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders Targeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders Richard D. Press, MD, PhD Dept of Pathology Knight Cancer Institute Knight Diagnostic Labs Oregon Health & Science University

More information

Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer

Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%

More information

Fusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas

Fusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas Fusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas Igor Astsaturov Philip Ellis Jeff Swensen Zoran Gatalica David Arguello Sandeep Reddy Wafik El-Deiry Disclaimers Dr. Igor

More information

Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight

Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight Co-Moderators: Rick Winneker, PhD, Senior Vice President, Research, Leukemia & Lymphoma Society Mike

More information

What is the status of the technologies of "precision medicine?

What is the status of the technologies of precision medicine? Session 2: What is the status of the technologies of "precision medicine? Gideon Blumenthal, MD, Clinical Team Leader, Thoracic and Head/Neck Oncology, Center for Drug Evaluation and Research (CDER), U.S.

More information

The Past, Present, and Future of Acute Myeloid Leukemia

The Past, Present, and Future of Acute Myeloid Leukemia The Past, Present, and Future of Acute Myeloid Leukemia Carter T. Davis, MD Hematology-Oncology Fellow Duke University Health System September 10, 2016 Overview Overview of Acute Myeloid Leukemia Review

More information

Myelodysplastic syndromes and the new WHO 2016 classification

Myelodysplastic syndromes and the new WHO 2016 classification Myelodysplastic syndromes and the new WHO 2016 classification 32nd General Annual Meeting of the Belgian Hematology Society 10-11 February 2017 Gregor Verhoef, Departement of Hematology, University Hospital

More information

Genetic complexity in MPN, MDS/MPN and MDS

Genetic complexity in MPN, MDS/MPN and MDS Genetic complexity in MPN, MDS/MPN and MDS Nick Cross Wessex Regional Genetics Laboratory, Salisbury Faculty of Medicine, University of Southampton Genetic complexity in chronic myeloid neoplasms Classes

More information

Cardiovascular Molecular Cytogenetics Methylenetetrahydrofolate Oligodendrogliomas Reductase (MTHFR) Mutation SS18 (C677T & A1298C) QF-PCR Sample:

Cardiovascular Molecular Cytogenetics Methylenetetrahydrofolate Oligodendrogliomas Reductase (MTHFR) Mutation SS18 (C677T & A1298C) QF-PCR Sample: Genetics Testing Dorevitch Pathology offers a comprehensive range of molecular and cytogenetic tests covering a wide spectrum of clinical indications to help in the diagnosis, management and treatment

More information

Anatomic Molecular Pathology: An Emerging Field

Anatomic Molecular Pathology: An Emerging Field Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty

More information

UNIVERSITY OF PENNSYLVANIA GENETIC DIAGNOSTIC LABORATORY

UNIVERSITY OF PENNSYLVANIA GENETIC DIAGNOSTIC LABORATORY GNA FOP Familial Adenomatous Polyposis Beckwith-Wiedemann Syndrome Methylation and high resolution copy number analysis of 11p15.5 with automatic reflex to CDKN1C if negative Methylation analysis of 11p15.5

More information

Intro alla patologia. Giovanni Barosi. Fondazione IRCCS Policlinico San Matteo Pavia

Intro alla patologia. Giovanni Barosi. Fondazione IRCCS Policlinico San Matteo Pavia Settima Giornata Fiorentina dedicata ai pazienti con malattie mieloproliferative croniche Sabato 13 Maggio 2017 CRIMM Centro di Ricerca e Innovazione per le Malattie Mieloproliferative AOU Careggi Intro

More information

TECHNICAL NOTICE. The CPT coding in this notice is effective January 1, 2013 and replaces the coding currently in use for these assays

TECHNICAL NOTICE. The CPT coding in this notice is effective January 1, 2013 and replaces the coding currently in use for these assays TECHNICAL NOTICE The CPT coding in this notice is effective January 1, 2013 and replaces the coding currently in use for these assays December 2012 The notation (MAAA) indicates "Multianalyte Assay with

More information

The mutations that drive cancer. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

The mutations that drive cancer. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge The mutations that drive cancer Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Previously on Cancer... hereditary predisposition Normal Cell Slightly

More information

2402: Pre-TED Disease Classification

2402: Pre-TED Disease Classification 2402: Pre-TED Disease Classification The Pre-TED Form is now required for all transplants, including subsequent transplants on * the comprehensive report form track. All transplant centers participating

More information

Lynch Syndrome Screening for Endometrial Cancer: Basic Concepts 1/16/2017

Lynch Syndrome Screening for Endometrial Cancer: Basic Concepts 1/16/2017 1 Hi, my name is Sarah Kerr. I m a pathologist at Mayo Clinic, where I participate in our high volume Lynch syndrome tumor testing practice. Today I hope to cover some of the basics needed to understand

More information

Follicular Lymphoma: the WHO

Follicular Lymphoma: the WHO Follicular Lymphoma: the WHO and the WHERE? Yuri Fedoriw, MD Associate Professor of Pathology and Laboratory Medicine Director of Hematopathology University of North Carolina Chapel Hill, NC Disclosure

More information

SH A CASE OF PERSISTANT NEUTROPHILIA: BCR-ABL

SH A CASE OF PERSISTANT NEUTROPHILIA: BCR-ABL SH2017-0124 A CASE OF PERSISTANT NEUTROPHILIA: BCR-ABL NEGATIVE John R Goodlad 1, Pedro Martin-Cabrera 2, Catherine Cargo 2 1. Department of Pathology, NHS Greater Glasgow & Clyde, QEUH, Glasgow 2. Haematological

More information

Genetic Predisposition Syndromes in Myeloid Malignancies

Genetic Predisposition Syndromes in Myeloid Malignancies Genetic Predisposition Syndromes in Myeloid Malignancies Lucy A. Godley, M.D., Ph.D. Section of Hematology/Oncology Departments of Medicine and Human Genetics The University of Chicago My patients and

More information

Colon cancer: practical molecular diagnostics. Wade S. Samowitz, M.D. University of Utah and ARUP

Colon cancer: practical molecular diagnostics. Wade S. Samowitz, M.D. University of Utah and ARUP Colon cancer: practical molecular diagnostics Wade S. Samowitz, M.D. University of Utah and ARUP Disclosure Dr. Samowitz may receive royalties in the future related to the Ventana BRAF V600E antibody.

More information

NEW IHC A n t i b o d i e s

NEW IHC A n t i b o d i e s NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology

More information

Acute myeloid leukemia

Acute myeloid leukemia Acute myeloid leukemia the molecular pathogenesis Pr Violaine Havelange, MD, PhD Hematological department Acute myeloid leukemia (AML) Incidence : 3-5 cases/100.000 population 80% of acute leukemias in

More information

Case #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back...

Case #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back... Case #16: Diagnosis T-Lymphoblastic lymphoma But wait, there s more... A few weeks later the cytogenetics came back... 46,XY t(8;13)(p12;q12)[12] Image courtesy of Dr. Xinyan Lu Further Studies RT-PCR

More information

CYTOGENETICS INTRODUCTION SPECIAL INSTRUCTIONS ON SAMPLE COLLECTION AND HANDLING

CYTOGENETICS INTRODUCTION SPECIAL INSTRUCTIONS ON SAMPLE COLLECTION AND HANDLING INTRODUCTION The Cytogenetics Laboratory offers a comprehensive array of chromosome investigations for cancers, constitutional abnormalities, and prenatal and postnatal diagnosis. Analyses are performed

More information

Familial and Hereditary Colon Cancer

Familial and Hereditary Colon Cancer Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of

More information

Learn your genetic risk for the most common hereditary cancers.

Learn your genetic risk for the most common hereditary cancers. Learn your genetic risk for the most common hereditary cancers. color.com Color analyzes 30 genes including BRCA1 and BRCA2 to help women and men understand their risk for the most common hereditary cancers,

More information

Yes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.

Yes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit. Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is

More information

Family Assessment. Objectives. Comprehensive Family History Important Inexpensive Underutilized genetic tool

Family Assessment. Objectives. Comprehensive Family History Important Inexpensive Underutilized genetic tool Besides the BRCA genes, what else to consider in hereditary breast and ovarian cancer? Laurie M. Connors DNP, APNG, FNP-BC, AGN-BC Objectives Evaluate personal & family history to assess risk for hereditary

More information

American Society of Cytopathology Core Curriculum in Molecular Biology

American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 1 Molecular Basis of Cancer Molecular Oncology Keisha

More information

Test Utilization: Chronic Lymphocytic Leukemia

Test Utilization: Chronic Lymphocytic Leukemia Test Utilization: Chronic Lymphocytic Leukemia Initial Evaluation Diagnostic Criteria Selection of Tests for Prognosis Response to Therapy Challenges Assessment for persistent disease Paul J. Kurtin, M.D.

More information

MET skipping mutation, EGFR

MET skipping mutation, EGFR New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM

More information

Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, San Diego CA

Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, San Diego CA Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, 2016 - San Diego CA ASH 2016 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://ash.confex.com/ash/2016/webprogram/start.html

More information

Next Generation Sequencing Assays in Primary and Metastatic Breast Cancers: Implications for Clinical Practice

Next Generation Sequencing Assays in Primary and Metastatic Breast Cancers: Implications for Clinical Practice Next Generation Sequencing Assays in Primary and Metastatic Breast Cancers: Implications for Clinical Practice Lajos Pusztai, MD, DPhil Professor of Medicine Chief of Breast Medical Oncology Co-Director

More information

GPS Cancer. The Era of Complete Genomics and Proteomics is Here. Advanced molecular profiling to inform personalized treatment strategies

GPS Cancer. The Era of Complete Genomics and Proteomics is Here. Advanced molecular profiling to inform personalized treatment strategies MOLECULAR PROFILING GPS Cancer The Era of Complete Genomics and Proteomics is Here Advanced molecular profiling to inform personalized treatment strategies www.nanthealth.com What information do you need

More information

UNIVERSITY OF PENNSYLVANIA GENETIC DIAGNOSTIC LABORATORY. Name of Test Turnaround Time Cost CPT codes

UNIVERSITY OF PENNSYLVANIA GENETIC DIAGNOSTIC LABORATORY. Name of Test Turnaround Time Cost CPT codes Beckwith-Wiedemann: methylation and copy number 3-4 weeks $800 81401x2, 81402, 81403 Beckwith-Wiedemann: CDKN1C sequencing 3 weeks $600 81404 Beckwith-Wiedemann: prenatal diagnosis for methylation and

More information

Molecular Testing of Solid and Hematologic Tumors and Malignancies

Molecular Testing of Solid and Hematologic Tumors and Malignancies Clinical Appropriateness Guidelines Molecular Testing of Solid and Hematologic Tumors and Malignancies EFFECTIVE OCTOBER 14, 2017 Appropriate.Safe.Affordable 2017 AIM Specialty Health 2066-1017 Table of

More information

Contractor Information

Contractor Information Local Coverage Determination (LCD): MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease (L36186) Links in PDF documents are not guaranteed to work. To follow a web link, please use the

More information

Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia

Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia Hackl et al. Journal of Hematology & Oncology (2017) 10:51 DOI 10.1186/s13045-017-0416-0 REVIEW Open Access Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid

More information

GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome

GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By HENRY T. LYNCH, M.D. 1 Could this be hereditary Colon Cancer 4 Creighton University School of Medicine Omaha, Nebraska Magnitude of the Problem Annual

More information

Myelodysplastic Syndromes:

Myelodysplastic Syndromes: Incidence Rate per 100,000 7/21/2015 Myelodysplastic Syndromes: Current Thinking on the Disease, Diagnosis and Treatment Rafael Bejar MD, PhD Aplastic Anemia & MDS International Foundation Regional Patient

More information

Acute myeloid leukemia: a comprehensive review and 2016 update

Acute myeloid leukemia: a comprehensive review and 2016 update OPEN Citation: (2016) 6, e441; doi:10.1038/bcj.2016.50 www.nature.com/bcj REVIEW Acute myeloid leukemia: a comprehensive review and 2016 update I De Kouchkovsky 1 and M Abdul-Hay 1,2 Acute myeloid leukemia

More information

Heme fusion assay. Valentina Nardi, MD Assistant pathologist Massachusetts General Hospital Assistant Professor Harvard Medical School

Heme fusion assay. Valentina Nardi, MD Assistant pathologist Massachusetts General Hospital Assistant Professor Harvard Medical School Heme fusion assay Valentina Nardi, MD Assistant pathologist Massachusetts General Hospital Assistant Professor Harvard Medical School No personal disclosures/conflicts of interest Kinase fusions in solid

More information

MPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs

MPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs MPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs Hans Michael Kvasnicka University of Frankfurt, Germany hans-michael.kvasnicka@kgu.de Disclosure of

More information

MDS/MPN: What it is and How it Should be Treated?

MDS/MPN: What it is and How it Should be Treated? MDS/MPN: What it is and How it Should be Treated? MDS MPN Rachel Salit, MD Assistant Member Fred Hutchinson Cancer Research Center rsalit@fredhutch.org MDS Founda>on Pa>ent & Family Forum: May 20, 2017

More information

Department of Pathology Presentation to Dr. Garcia

Department of Pathology Presentation to Dr. Garcia Department of Pathology Presentation to Dr. Garcia UAHN Clinical Laboratories September 8, 2014 Presented by: Maria Proytcheva, MD Medical Director, UAHN Laboratories 0 UAHN Clinical Laboratories Meghan

More information

RUNX1 and FPD/AML Translational Research. The Leukemia and Lymphoma Society / Babich Family Foundation Partnership. September 2016

RUNX1 and FPD/AML Translational Research. The Leukemia and Lymphoma Society / Babich Family Foundation Partnership. September 2016 www.lls.org www.runx1.com RUNX1 and FPD/AML Translational Research The Leukemia and Lymphoma Society / Babich Family Foundation Partnership September 2016 Prepared by L. Greenberger, PhD Chief Scientific

More information

GENETIC ANALYSIS OF FAMILIAL MYELOID DISORDERS. PhD Thesis. Dr. Péter Attila Király. Semmelweis University Doctoral School of Pathological Sciences

GENETIC ANALYSIS OF FAMILIAL MYELOID DISORDERS. PhD Thesis. Dr. Péter Attila Király. Semmelweis University Doctoral School of Pathological Sciences GENETIC ANALYSIS OF FAMILIAL MYELOID DISORDERS PhD Thesis Dr. Semmelweis University Doctoral School of Pathological Sciences Supervisor: Csaba Bödör, PhD Official reviewers: Laura Horváth, MD, PhD Alizadeh

More information

Introduction. Why Do MSI/MMR Analysis?

Introduction. Why Do MSI/MMR Analysis? Clinical Significance Of MSI, KRAS, & EGFR Pathway In Colorectal Carcinoma UCSF & Stanford Current Issues In Anatomic Pathology Introduction Microsatellite instability and mismatch repair protein deficiency

More information

Molecular Diagnostics for Myeloproliferative Neoplasms. Noah Brown, MD April 16, 2015

Molecular Diagnostics for Myeloproliferative Neoplasms. Noah Brown, MD April 16, 2015 Molecular Diagnostics for Myeloproliferative Neoplasms Noah Brown, MD April 16, 2015 Outline 1. Brief MPN Introduction 2. When/How Should Molecular Testing be Performed? 3. JAK2 V617F Mutation Testing

More information

DNA Genetic Cancer Risk Test. Test Report

DNA Genetic Cancer Risk Test. Test Report Test Report CONTENTS SECTION 1 1-1. Customer Information 1-2. Test Report Summary 1-3. Test Report Details 1-4. List of Cancers / Tumors Tested SECTION 2 2-1. About the Test 2-2. References 1 CL0040-1_B

More information

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives 2008 Oncology Pharmacy Preparatory Review Course Learning Objectives Session 1 Symptom Management, Part I, II & III Teresa A. Mays, Pharm D., BCOP Director, Investigational Drug Department San Antonio,

More information

Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities

Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities Acute Myeloid Leukemia with recurrent cytogenetic Abnormalities -t(8;21)(q22;q22)(aml/eto) -inv(16) or t(16;16) -t(15;17) -11q23 Acute Myeloid

More information

GENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute

GENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute GENETIC MARKERS IN LYMPHOMA a practical overview P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute B and T cell monoclonalities Rearrangement of immunoglobin and TCR genes may help

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the author to give readers additional information about his work. Supplement to: Croce CM. Oncogenes and cancer. N Engl J Med 2008;358:502-11.

More information

MYELODYSPLASTIC SYNDROMES: A diagnosis often missed

MYELODYSPLASTIC SYNDROMES: A diagnosis often missed MYELODYSPLASTIC SYNDROMES: A diagnosis often missed D R. EMMA W YPKEMA C O N S U LTA N T H A E M AT O L O G I S T L A N C E T L A B O R AT O R I E S THE MYELODYSPLASTIC SYNDROMES DEFINITION The Myelodysplastic

More information

TP53 mutational profile in CLL : A retrospective study of the FILO group.

TP53 mutational profile in CLL : A retrospective study of the FILO group. TP53 mutational profile in CLL : A retrospective study of the FILO group. Fanny Baran-Marszak Hopital Avicenne Bobigny France 2nd ERIC workshop on TP53 analysis in CLL, Stresa 2017 TP53 abnormalities :

More information

Bihong Zhao, M.D, Ph.D Department of Pathology

Bihong Zhao, M.D, Ph.D Department of Pathology Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories

More information

Acute Myeloid Leukemia

Acute Myeloid Leukemia Acute Myeloid Leukemia Effective Date: June, 2017 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team and are a synthesis of currently accepted

More information

Clinical Quality Assurance Measures at Myriad Genetic Laboratories:

Clinical Quality Assurance Measures at Myriad Genetic Laboratories: Clinical Quality Assurance Measures at Myriad Genetic Laboratories: Increasing the Clinical Utility and Cost-Effectiveness of Genetic Testing for Hereditary Cancer Syndromes for Patients, Healthcare Providers

More information

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:

More information

Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1+)

Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1+) Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1+) Version: CMLBiomarkers 1.0.0.2 Protocol Posting Date: June 2017 This biomarker template is

More information

BRCA 1/2. Breast cancer testing THINK ABOUT TOMORROW, TODAY

BRCA 1/2. Breast cancer testing THINK ABOUT TOMORROW, TODAY BRCA 1/2 Breast cancer testing THINK ABOUT TOMORROW, TODAY 5 10% of patients with breast and/or ovarian cancer have a hereditary form1. For any individual carrying a mutation in BRCA1 or BRCA2, the lifetime

More information

DKTK Local Retreat Partner Site Freiburg

DKTK Local Retreat Partner Site Freiburg DKTK Local Retreat Partner Site Freiburg November 20 21, 2017 Restaurant Dattler Am Schlossberg 1 Freiburg Talks Day 1, Nov. 20 Session No. Time Chair Talks Intro 08:50 Christoph Peters Early Diagnosis

More information

Clinical Cancer Genetics

Clinical Cancer Genetics Clinical Cancer Genetics Lisen Axell, MS, CGC University of Colorado Cancer Center Individuals with cancer Making surgical decisions (lump vs. mast) Making treatment decisions (XRT) Concerns for additional

More information

Minimal residual disease (MRD) in AML; coming of age. Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital

Minimal residual disease (MRD) in AML; coming of age. Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital Minimal residual disease (MRD) in AML; coming of age Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital 1. The logistics of MRD assessment in AML 2. The clinical

More information

4 th Annual conference on. gynecologic oncology. JULY 18-19, 2018 Atlanta, USA.

4 th Annual conference on. gynecologic oncology. JULY 18-19, 2018 Atlanta, USA. 4 th Annual conference on gynecologic oncology JULY 18-19, Atlanta, http://gynecologic-oncology.conferenceseries.com/ Invitation Dear Attendees, We are glad to announce the 4 th Annual Conference on Gynecologic

More information

John L Frater, MD Jeffery M Klco, MD, PhD Department of Pathology and Immunology Washington University School of Medicine St Louis, Missouri

John L Frater, MD Jeffery M Klco, MD, PhD Department of Pathology and Immunology Washington University School of Medicine St Louis, Missouri Myeloproliferative Neoplasms: New Approaches to Diagnosis and Disease Monitoring John L Frater, MD Jeffery M Klco, MD, PhD Department of Pathology and Immunology Washington University School of Medicine

More information

HEMATOLOGY AND ONCOLOGY

HEMATOLOGY AND ONCOLOGY x THE POWER OF HEMATOLOGY AND ONCOLOGY Experts. Experience. Execution. A Deeper Dive into Hematology and Oncology Medpace supports our sponsors who are advancing new anti-cancer therapies by providing

More information

Whole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute

Whole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes

More information

Oncology Drug Development

Oncology Drug Development Oncology Drug Development Advantages and challenges of using stratified clinical studies Simon J Hollingsworth The 18th Anti-Tumour Drug Development Forum 21 February Japan Stratified Medicine In The Clinic

More information

GENOPTIX DELIVERS CLEAR, COMPREHENSIVE, AND CLINICALLY ACTIONABLE RESULTS

GENOPTIX DELIVERS CLEAR, COMPREHENSIVE, AND CLINICALLY ACTIONABLE RESULTS TESTING DIRECTORY APRIL 2017 GENOPTIX DELIVERS CLEAR, COMPREHENSIVE, AND CLINICALLY ACTIONABLE RESULTS Genoptix Medical Laboratory 2110 Rutherford Road Carlsbad, CA 92008 Phone: 760.268.6200 Fax: 760.268.6201

More information